Sensible Biotechnologies
Unlocking the next generation of mRNA medicines
About Sensible Biotechnologies
The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
Company details
Funding
Total raised
$48.5M
Last stage
Seed
Investors
Founders
Marian Kupculak
I am Marian, the Chief Scientific Officer and co-founder of Sensible Biotechnologies. We are building a new platform for cost-efficient and scalable manufacturing of high-quality mRNA. I have more than 9 year of experience in biochemistry and molecular biology, more specifically in cellular engineering and downstream processing. I am interesting in engineering cells to produce high-quality proteins and nucleic acids. I did my PhD in Biochemistry at the University of Oxford, UK.
LinkedIn
Miroslav Gasparek
Bioengineering degree from Imperial College London; research at Imperial, Caltech and Stanford. Advised Slovak Ministry of Health on biosecurity and innovation.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.